TSX •
Healthcare •
Biotechnology •
Quote as of 09/02/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeTSX
Market Capitalization1.99 mln
Float118 mln
Earnings Date11/13/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
64
/ 100
Outperforming
Debt / Equity
-0.70
Negative equity
Pre-Tax Margin
-1,269%
Severely loss-making
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Appili Therapeutics is a Canadian company founded in 2015 and based in Halifax, focused on finding and developing new treatments for infectious diseases that currently lack good options. Its pipeline includes three key products: a child-friendly liquid form of the antibiotic metronidazole, a topical treatment for a parasitic skin disease called cutaneous leishmaniasis, and a vaccine targeting a rare but dangerous bacterial infection known as tularemia.
